Occult hepatitis B (OHB) infection is still a topic of debate worldwide. It is defined as the presence of HBV-DNA in the liver with HBV-DNA detectable or not in the serum, without detectable HBsAg ([@B15]). Some researchers have noted that OHB could be associated with the risk for the reactivation of HBV infection in patients subjected to long-term immunosuppression ([@B10], [@B19]). In addition, OHB may be related to chronic hepatitis of unknown aetiology, cirrhosis and hepatocellular carcinoma ([@B05], [@B18]).

Current evidence indicates that there is a high prevalence of OHB infection among dialysis patients ([@B02], [@B01], [@B13], [@B16]); however, the prevalence of OHB infection among kidney transplant recipients remains controversial, with few published data on this subject ([@B14], [@B03]).

End-stage renal disease (ESRD) patients may be at risk for OHB infection due to their use of haemodialysis and history of blood transfusions ([@B12], [@B02], Di Stefano et al. 2009).

The aim of this study was to determine the frequency of OHB among kidney transplant recipients and identify the related factors. A cross-sectional study was performed in a low-HBsAg endemicity area from November 2008-May 2010. The study sample included HBsAg-negative kidney transplant recipients seen at the Renal Transplantation Unit of the Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil. This study was approved by the Ethical Committee of the Federal University of Rio de Janeiro, Brazil (protocol 118/2008). Patients were recruited during regular appointments and written consent was obtained.

All patients were screened for the following serological markers of HBV and hepatitis C virus (HCV): HBsAg (Liaison, Diasorin, Italy), hepatitis B core antibody (anti-HBc) and hepatitis B surface antibody (anti-HBs) (Liaison, Diasorin, Italy) and anti-HCV (3rd-generation ELISA, Murex, Abbot, South Africa). The exclusion criteria were human immunodeficiency virus (HIV) infection and chronic HBV infection.

HBV-DNA was extracted from 200 µL of plasma using the QIAamp^(r)^ MinElute Virus Spin Kit (Qiagen). The extracted DNA was stored at -70^o^C until analysis by real-time polymerase chain reaction (RT-PCR). The RT-PCR was performed with the Step One Plus kit (Applied Biosystems) and the sequences of the primers and the probe were as follows: HBVRSV (AGAATCCTCACAATACCGCAGAGT), HBVRSL (CACACGGTAGTTCCC CCTAGAA) and HBVPS (FAMAGACTCGTGGTGGACTTCTCTCAATTAMRA). The primers and probe targeted the X region of the viral genome. The Taqman^(r)^ Universal PCR Master Mix (Applied Biosystems) was used for this reaction with the following amplification conditions: 35 cycles of denaturation for 30 s at 94°C, annealing for 45 s at 56°C and extension for 1.5 min at 72°C. Serum samples that were positive in at least two of the three PCR assays were considered HBV-DNA positive and the patient was diagnosed with OHB infection. The lower limit of detection of the PCR assay was 3 IU/mL. The samples collected for the study were all tested in duplicate.

A total of 207 HBsAg-negative kidney transplant recipients were included in this study. The demographic, clinical and laboratory data are shown in [Table I](#t01){ref-type="table"} .

TABLE IDemographic and clinical characteristics of kidney transplant recipients (n = 207)Age (years)-45 ± 12Male gender \[n (%)\]-105 (51)Donor \[n (%)\]Living108 (52) Cadaver99 (48)Type of dialysis \[n (%)\]Haemodialysis197 (95) Peritoneal dialysis13 (6) None4 (2)Time on dialysis (months) (mean ± SD)-50 (± 42)  Min-max 0-156Time transplanted (months) (mean ± SD)-82 (± 38)  Min-max 13-122Transfusion \[n (%)\]-133 (64)Drug injection user \[n (%)\]-3 (1)HBV vaccination \[n (%)\]Yes130 (62) No17 (9) Not available60 (29)Primary disease \[n (%)\]Chronic glomerulonephritis64 (31) Hypertensive nephropathy43 (21) Diabetic nephropathy16 (8) Undefined55 (26) Others29 (14)Type of immunosuppression \[n (%)\]Prednisone/sirolimus/MMF71 (34) Prednisone/tacrolimus/MMF42 (21) Sirolimus/MMF29 (14) Others65 (31)Isolated anti-HBc \[n (%)\]-2 (1)Anti-HBc + anti-HBs \[n (%)\]-10 (5)Anti-HBs \[n (%)\]-114 (55)Anti-HCV \[n (%)\]-25 (12)ALT (IU/mL)-22Elevated ALT \[n (%)\]-46 (22)GGT (IU/mL) (median)-36Elevated GGT \[n (%)\]-67 (32)HBV-DNA (PCR) \[n (%)\]-2 (1)[^1]

Among the 207 HBsAg-negative patients, two had detectable levels of HBV-DNA, indicating that these patients had OHB infection. Serological markers of HBV infection were not detected in either of these patients. The primary finding of the present study was a very low prevalence of OHB among kidney transplant recipients (1%), as previously observed in two similar studies, one by [@B14] and the other by [@B03]; these studies found prevalence of 2% and 2.7%, respectively. The demographic and laboratory data for the OHB infection patients are shown in [Table II](#t02){ref-type="table"} .

TABLE IIDemographic and laboratory data of the HBV-DNA positive kidney transplant recipientsPatients12GenderMaleFemaleAge (years)4539Type of dialysisHaemodialysisHaemodialysisTime on dialysis (months)415Time after transplant (years)96DonorLivingCadaverTransfusionNoneNoneDrug injection useNoneNoneHBV vaccinationNot sureYesImmunosuppressionPrednisone/sirolimus/MMFPrednisone/sirolimus/MMFPrimary diseaseHypertensive nephropathyDiabetic nephropathyHBV serology pre transplant    Anti-HBsNegativeNegative  Anti-HBcNegativeNegativeHBV serology pos transplant    Anti-HBsNegativeNegative  Anti-HBcNegativeNegativeAnti-HCVNegativeNegativeALTNormalNormalGGTNormalNormalHBV-DNA (UI/mL)3.53.1[^2]

The prevalence of OHB infection among renal dialysis patients ranged from 0-50% in previously published studies ([@B09], [@B02], [@B19], [@B01], [@B13], [@B16]). The wide range of OHB infection prevalence could be the result of many factors, such as the use of different assays for HBV-DNA detection, viral load (VL) fluctuation in this population and different geographic HBV prevalence among the studied regions.

The 207 kidney transplant recipients included in this study were similar, with respect to the distributions of age, gender and time on dialysis, to the patient populations used in the studies by [@B14] and [@B03] . [@B14] used a nested PCR with a limit of detection of 104 copies/mL, whereas in the present study and the study by [@B03], the RT-PCR assays had lower limits of detection of 3 IU/mL (16 copies/mL) and 2 IU/mL (11 copies/mL), respectively. It is important to use a PCR assay with a low limit of detection because the VL is usually lower than 200 IU/mL (1000 copies/ml) in OHB patients according to [@B15] .

ESRD patients and kidney transplant recipients have a lower rate of seroconversion after HBV vaccination than the general population. Not only is the seroconversion rate lower, but the anti-HBs levels in those patients who do seroconvert also decline more quickly after immunisation than in healthy individuals ([@B04], [@B06]). These factors could be related to the absence of anti-HBs in most of these patients (such as patient 2) ([Table II](#t02){ref-type="table"}).

Liver enzyme abnormalities are not common in OHB patients ([@B01], [@B03]); therefore, the normal levels of alanine aminotransferase (ALT) and gamma-glutamil transferase (GGT) found in our study were expected. These normal levels may suggest that OHB infection is a silent infection that does not affect liver biochemistry or liver function. However, these patients should be followed and evaluated on a long-term basis to better understand the outcome and the clinical impact of OHB infection in this specific population.

Although HBV and HCV infections share a common epidemiological pattern, an association between OHB and HCV has not been clearly established. A higher prevalence of OHB has been found in some studies that evaluated chronic HCV-infected patients ([@B11], [@B17], [@B08] ). Although 12% of patients in the present study were anti-HCV-positive, no HBV-DNA was detected in any of these patients. In the study by [@B03], in which there was a 3% prevalence of HCV-infected patients, no HBV-DNA was detected in any of the HCV-positive patients, as found in our study.

It is possible that the low OHB prevalence observed in this study may reflect the immunosuppressed state of the patients, which could have a permissive effect on HBV replication. However, immunosuppressed patients would be expected to have high HBV VLs and the low VLs associated with OHB infection would be an exception.

In conclusion, the prevalence of OHB infection is low among kidney transplant recipients, possibly due to the low HBsAg endemicity of the general population in the study area. Longitudinal studies focused on the mechanism of OHB infection and its clinical outcomes are required to better understand this entity.

[^1]: ALT: alanine aminotransferase; GGT: gama-glutamyl transpeptidase; anti-HBc: hepatitis B core antibodies; anti-HBs: hepatitis B surface antibodies; HBV: hepatitis B virus; HCV: hepatitis C virus; MMF: mycophenolate mofetil; PCR: polymerase chain reaction; SD: standard deviation.

[^2]: ALT: alanine aminotransferase; GGT: gama-glutamyl transpeptidase; anti-HBc: hepatitis B core antibodies; anti-HBs: hepatitis B surface antibodies; HBV: hepatitis B virus; HCV: hepatitis C virus; MMF: mycophenolate mofetil.
